Zydus Cadila gets US regulator nod for Emtricitabine & Tenofovir Disoproxil Fumarate tablets
On Thursday, Zydus Cadila announced that it has received tentative approval from United States Food & Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg.
Emtricitabine and Tenofovir Disoproxil Fumarate tablets are used along with other HIV medications to help control the infection. The combination of the two drugs is used to decrease the amount of HIV in the body so that the immune system can work better.
In a press release to BSE, the company stated that the above-mentioned drug will be manufactured at its SEZ Ahmedabad manufacturing facility. The pharmaceutical group now has over 400 ANDAs filed since the commencement of the filing process in FY04.
At the time of market closing today, the shares of Zydus Cadila were trading at Rs 419.55, down by 2.75 per cent or Rs 11.85 per share, against a 1.73 per cent decline in the benchmark index. The 52-week high of the company is recorded at Rs 509.35 while its 52-week low is Rs 248 on BSE.